NINDS encourages grant applications to validate novel therapeutic targets for Huntington’s disease. This announcement is made together with the CHDI Foundation, Inc.
Huntington’s disease is an inherited neurodegenerative disorder characterized by cognitive and memory impairments, heightened irritability, depression, weight loss, and choreic motor abnormalities. Roughly 120,000 Americans carry the expanded CAG repeat sequence in the huntingtin gene that causes this fatal disease. A well-characterized understanding of the biological basis for Huntington’s disease pathophysiology is necessary to accelerate the development of disease-modifying treatments.
Application Due Date: October 5, 2010
Potential applicants should contact Dr. Margaret Sutherland, program director, Neurodegeneration Cluster, NINDS, at 301-496-5680; email: or email@example.com. For more information visit http://grants.nih.gov/ grants/guide/pa-files/PAS-10-183.html.